OTC : AMEUF

Anteris Technologies Ltd

$5.7 USD

-$3.18 (-35.81%)

Volume
100
Average Volume
2.14K
Market Capitalization
$120.5M
P/E Ratio
-3.35
Dividend Yield
0.00%
Price Target
Year High
$15.53
Year Low
$5.55
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$0.73
Company Overview

OTC

Wayne Geoffrey Paterson

Medical - Devices

Healthcare

AMEUF

N/A

AU

USD

https://www.anteristech.com

61 13 0055 0310

N/A

N/A

Liquidity Metrics

-24.54

0.73

0.73

0.59

0.00

Sales & Valuation

$4.37M

174.74

-3130.96

-7.62

-1.08

Profitability

-$6.09

-$123.26M

-5115.59%

-5115.73%

-715.34%

-378.14%

P/E Metrics

-3.35

-0.08

-0.08

Analyst Price Target & Rating

N/A

0/5

0 Analysts

%

Poll Results

About Anteris Technologies Ltd (OTC:AMEUF) Stock

Anteris Technologies Ltd. is a medical device company focused on structural heart solutions. The firm manufactures and commercializes ADAPT, an advanced regenerative tissue product. Additionally, Anteris is actively developing DurAVRTM, a novel 3D, single-piece aortic valve designed to treat aortic stenosis. The company also conducts research and development in the broader field of regenerative medicines. Established in 1999, it changed its name from Admedus Limited to Anteris Technologies Ltd. in May 2020 and is headquartered in Toowong, Australia. ...

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

2026-06-08 06:00:00

MINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This authorization marks a significant milestone in the Company's clinical and regulatory strategy and enables patient recruitment to commence at leading centers in France.

Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors

2026-05-13 08:39:00

MINNEAPOLIS and BRISBANE, Australia, May 13, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced the appointment of Ms. Susan Knight and Mr.

Anteris Announces Results for the First Quarter of 2026

2026-05-12 19:00:00

MINNEAPOLIS and BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. Q1 2026 Highlights Completed aggregate capital raises totalling $320 million in January 2026 to support execution of the PARADIGM Trial and advance the Company toward global commercialization of the DurAVR® THV System Advanced PARADIGM Trial recruitment, supported by ongoing regulatory and operational work to activate additional countries and sites – post quarter-end, U.S. enrollment commenced Presented clinical data from the ongoing EMBARK Study and U.S. Early Feasibility Study (EFS) at Cardiovascular Research Technologies (CRT 2026) and Sydney Valves 2026, supporting ongoing scientific engagement and exchange with the clinical community “Q1 2026 reflects strong execution across the PARADIGM Trial, with patient enrollment ongoing in Europe and continued progress on key recruitment activities globally.

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

2026-05-05 06:00:00

MINNEAPOLIS and BRISBANE, Australia, May 05, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that the first patients in the United States have been enrolled and successfully treated in the DurAVR® Transcatheter Heart Valve (“THV”) global pivotal trial for patients with severe calcific aortic stenosis (the “PARADIGM Trial”). The procedures were performed by Azeem Latib, M.D.

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

2026-04-28 06:00:00

MINNEAPOLIS and BRISBANE, Australia, April 28, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced it has secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare & Medicaid Services (CMS) national coverage policy. Eligible procedures performed at participating U.S. study sites are covered under the Transcatheter Aortic Valve Replacement (TAVR) National Coverage Determination 20.32.

Frequently Asked Questions

What is the current Anteris Technologies Ltd (AMEUF) stock price?

Anteris Technologies Ltd(OTC:AMEUF) stock price is $5.7 in the last trading session. During the trading session, AMEUF stock reached the peak price of $15.53 while $5.55 was the lowest point it dropped to. The percentage change in AMEUF stock occurred in the recent session was --35.81% while the dollar amount for the price change in AMEUF stock was -$3.18.

AMEUF's industry and sector of operation?

The OTC listed AMEUF is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of AMEUF?

Stephen Denaro | Non-Executive Director & Company Secretary
Wayne Geoffrey Paterson | Chief Executive Officer, MD & Executive Director
David Denis | Chief Operating Officer
Matthew McDonnell | Chief Financial Officer
Chris Meduri | Chief Medical Officer & Member of Medical Advisory Board

How many employees does AMEUF have?

Number of AMEUF employees currently stands at None. AMEUF operates from Toowong Tower, Toowong, QLD 4066, AU.

Link for AMEUF official website?

Official Website of AMEUF is: https://www.anteristech.com

How do I contact AMEUF?

AMEUF could be contacted at phone #61 13 0055 0310 and can also be accessed through its website. AMEUF operates from Toowong Tower, Toowong, QLD 4066, AU.

How many shares of AMEUF are traded daily?

The average number of AMEUF shares traded daily for last 3 months was 2.14K.

What is the market cap of AMEUF currently?

The market value of AMEUF currently stands at $120.5M with its latest stock price at $5.7